A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

This study tests the combination of two drugs — cevostamab and elranatamab — both of which help the immune system attack multiple myeloma cells, in people whose myeloma has come back or stopped responding to prior treatments. **You may be eligible if...** - You have been diagnosed with relapsed or refractory multiple myeloma - Your general health score (ECOG) is 0 or 1 - You agree to use contraception if applicable **You may NOT be eligible if...** - You have previously received cevostamab or elranatamab - You have had an allogeneic stem cell transplant (donor transplant) - You have a history of autoimmune disease, amyloidosis, or certain nerve conditions - You have active hepatitis B, C, or HIV - You have a history of serious brain-related complications from prior therapy - You have significant heart disease - You have a history of a rare brain infection called PML Talk to your doctor to see if this trial is right for you.